Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03893682 · ClinicalTrials.gov registry record · Phase 1
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
A Phase 1 study, sponsored by Aptose Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03893682 is a Phase 1 study that was terminated before completion, run by Aptose Biosciences. The registered enrollment target is 36 participants.
The verdict
NCT03893682, a Phase 1 study, was terminated before completion, sponsored by Aptose Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.
Interventions
- DRUG CG-806
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2024-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03893682
The ClinicalTrials.gov registry entry for NCT03893682 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptose Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CG-806 is the first listed.
NCT03893682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03893682 about?
NCT03893682 is a clinical study titled "A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas". This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established the...
What is the current status of trial NCT03893682?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2019-04-30. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT03893682?
The interventions under investigation include: CG-806 (DRUG).
Who is sponsoring clinical trial NCT03893682?
This trial is sponsored by Aptose Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.